2005, Number 6
Next >>
Acta Pediatr Mex 2005; 26 (6)
Why three bolus of methylprednisolone?
Hernández-Bautista V, Yamazaki-Nakashimada MA
Language: Spanish
References: 9
Page: 297-298
PDF size: 22.93 Kb.
Text Extraction
No Abstract
REFERENCES
Buttgereit F, Brand MD, Burmester GR. Equivalent doses and relative drug potencies for non-genomic glucocorticoid effects: a novel glucocorticoid hierarchy. Biochem Pharm 1999;58:363-9.
Buttgereit F, Wehling M, Burmester GR. A new hypothesis of modular glucocorticoid actions. Arthritis Rheum 1998;41:761-7.
Buttgereit F, Da Silva JA, Boers M, et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis 2002;61:718-22.
Mandell B. Acute Rheumatoid and Immunological Diseases: management of the critically ill patient. Marcel Dekker Inc. 1994;pp527-39.
Hirschberg T, Randazzo B, Hirschberg H. Effects of methylprednisolone on the in vivo induction and function on suppressor cells in man. Scand J Immunol 1980;12:33.
Alvarez Valdes A. ¿Qué sabemos de la Biblia? Ed. Lumen 1995;pp5-8.
Keeene M. Cristianismo. Altea, Taurus, Alfaguara 2002;p44.
Cerisier A, Dacosta A, Brulport V, et al. Severe coronary events and corticoids bolus. An update apropos of 3 new cases. Arch Mal Coeur Vaiss 1997;90:1285-8.
Guillen EL, Ruiz AM, Bugallo JB. Hypotension, bradycardia, and asystole after high dose methylprednisolone in a monitored patient. Am J Kidney Dis 1998;32:e4.
Full text